In a brief press release, Actelion Ltd (SIX: ATLN) gave mixed news from its pivotal program comparing novel anti-infective cadazolid with the antibiotic vancomycin as a treatment for clostridium difficile-associated diarrhea (CDAD).
While one Phase III trial met its primary endpoint, a second did not. The company says the drug displayed “an acceptable tolerability and safety profile.”
The drug, which is described as a novel quinoxolidinone antibiotic, is designed to inhibit clostridium difficile protein synthesis, leading to suppression of toxin production and spore formation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze